US 12291566

US patent 12291566, titled "Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis," was filed on April 22, 2021, and issued on May 6, 2025. The current and original assignee is Janssen Biotech Inc. The inventors are Diane D. Harrison, Elizabeth C. Hsia, Lee-Lian Kim, and Kim Hung Lo.

Abstract:
The patent describes an isolated mammalian anti-TNF antibody with a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Ankylosing Spondylitis. It also covers compositions and methods for treating active Ankylosing Spondylitis using this anti-TNF antibody.

Independent Claims Overview:

• Independent Claim 1: This claim covers an isolated mammalian anti-TNF antibody designed for treating active Ankylosing Spondylitis. The treatment method involves administering the antibody to a diagnosed subject via intravenous (IV) infusion.

• Independent Claim 11: This claim describes a composition that includes an isolated mammalian anti-TNF antibody and a pharmaceutically acceptable carrier. This composition is intended for use in treating active Ankylosing Spondylitis by administering it intravenously (IV) to a patient diagnosed with the condition.

• Independent Claim 21: This claim outlines a method for treating active Ankylosing Spondylitis. The method involves administering a composition containing an isolated mammalian anti-TNF antibody to a diagnosed subject through intravenous (IV) infusion.

• Independent Claim 30: This claim pertains to an article of manufacture. It comprises packaging material and at least one vial containing a solution of an isolated mammalian anti-TNF antibody with a buffer, potentially in an aqueous diluent. The packaging includes a label indicating that the solution can be stored for a period of 1 to 72 hours or more.

USPTO and CAFC 2026 Dockets:
A search for US patent 12291566 indicates that the patent is currently active. The Google Patents record also shows that litigation related to this patent family has been filed. Specifically, a US case was filed in the Delaware District Court (case 1:26-cv-00222) and a PTAB case (IPR2026-00259) has been filed and is pending. No specific CAFC 2026 docket information was found that directly mentions a ruling or ongoing case at that appellate level at this time, beyond the indication of litigation in the district court and PTAB.


Note: The information regarding the legal status and litigation is based on the Google Patents record, which sources litigation data from Darts-ip and Unified Patents. These sources are considered reliable for indicating the presence of litigation, but a full legal analysis would require direct access to court and PTAB dockets.